The efficacy and safety of donafenib combined with transcatheter arterial chemoembolization and anti-PD-1 antibodies as first-line therapy for hepatocellular carcinoma: A retrospective study

被引：0
|
作者：
Song, Danjun
Hao, Weiyuan
Cao, Fei
Luo, Jun
Guo, Liwen
Zhang, Zhewei
Zheng, Jiaping
机构：
[1] Zhejiang Canc Hosp, Hangzhou, Zhejiang, Peoples R China
[2] Zhejiang Canc Hosp, Dept Intervent Radiol, Hangzhou, Zhejiang, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16178
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of donafenib combined with transcatheter arterial chemoembolization (TACE) and anti-PD1 antibody for the treatment of unresectable hepatocellular carcinoma (uHCC): A retrospective study
    Ge, Naijian
    Wang, Xiangdong
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [2] Lenvatinib Combined with Anti-PD-1 Antibodies Plus Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study
    Wu, Jia-Yi
    Yin, Zhen-Yu
    Bai, Yan-Nan
    Chen, Yu-Feng
    Zhou, Song-Qiang
    Wang, Shuang-Jia
    Zhou, Jian-Yin
    Li, Yi-Nan
    Qiu, Fu-Nan
    Li, Bin
    Yan, Mao-Lin
    JOURNAL OF HEPATOCELLULAR CARCINOMA, 2021, 8 : 1233 - 1240
  • [3] Efficacy of Lenvatinib Combined with Anti-PD-1 Antibodies Plus Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Retrospective, Multicenter Study
    Ou, Xiangye
    Wu, Junyi
    Wu, Jiayi
    Fu, Yangkai
    Zeng, Zhenxin
    Li, Shuqun
    Li, Yinan
    Liu, Deyi
    Li, Han
    Li, Bin
    Zhou, Jianyin
    Zhuang, Shaowu
    Cheng, Shuqun
    Zhang, Zhibo
    Wang, Kai
    Qu, Shuang
    Yan, Maolin
    CANCER RESEARCH AND TREATMENT, 2024, 56 (04): : 1207 - 1218
  • [4] Efficacy and Safety of Transcatheter Arterial Chemoembolization Combined with Lenvatinib Plus Anti-PD-1 Inhibitors for Hepatocellular Carcinoma Patients with Extrahepatic Metastases: A Multicenter Retrospective Study
    Liu, De-Yi
    Li, Yi-Nan
    Wu, Jia-Yi
    Zeng, Zhen-Xin
    Fu, Yang-Kai
    Li, Han
    Ou, Xiang-Ye
    Zhang, Zhi-Bo
    Wang, Shuang-Jia
    Wu, Jun-Yi
    Yan, Mao-Lin
    JOURNAL OF HEPATOCELLULAR CARCINOMA, 2024, 11 : 2339 - 2349
  • [5] Study on safety and efficacy of regorafenib combined with transcatheter arterial chemoembolization in the treatment of advanced hepatocellular carcinoma after first-line targeted therapy
    Wang, Haochen
    Xiao, Weizhong
    Han, Yanjing
    Cao, Shasha
    Zhang, Zhiyuan
    Chen, Guang
    Hu, Yuefeng
    Jin, Long
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2022, 13 (03) : 1248 - 1254
  • [6] Efficacy and safety of donafenib combined with anti-PD-1 antibodies for initially unresectable hepatocellular carcinoma (HCC): A retrospective real-world study.
    Liu, Sulai
    Zhou, Shuyi
    Song, Yinghui
    Liu, Jianming
    Guo, Chao
    Yang, Pingzhou
    Li, Ou
    Yi, Weimin
    Peng, Chuang
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [7] Donafenib combined with anti-PD-1 antibody and transarterial chemoembolization (TACE) as first-line (1L) treatment for unresectable/advanced hepatocellular carcinoma (HCC)
    Zhou, Jian
    Yan, Zhiping
    Wang, Zheng
    Qiu, Shuang-Jian
    Yang, Minjie
    Zhu, Kai
    Yi, Yong
    Yu, Lei
    Sun, Yun-Fan
    Zhang, Bo
    Yu, Jiaze
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [8] Donafenib combined with anti-PD-1 antibodies plus transarterial therapy for initially unresectable hepatocellular carcinoma
    Wen, Yaohong
    Fu, Shunjun
    He, Guolin
    Cai, Lei
    Liu, Yahong
    Li, Xinmin
    Xu, Yuyan
    Wang, Chunming
    Zhong, Kaihang
    Zhang, Cheng
    Xie, Qingyu
    Pan, Mingxin
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [9] The efficacy and safety of donafenib-containing regimens as first-line therapy for hepatocellular carcinoma (HCC): A multicenter retrospective study
    Zhang, Qingqiao
    Yin, Guowen
    Xu, Qingyu
    Xiao, Jinchang
    Shen, Bin
    Chen, Guofeng
    Zhang, Genshan
    Feng, Wei
    Yang, Yong
    Hu, Jianping
    Wang, Chenghu
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [10] Chemoembolization plus hepatic arterial infusion chemotherapy combined with donafenib, anti-PD-1 antibody for unresectable hepatocellular carcinoma (uHCC): A retrospective analysis.
    Yin, Linan
    Liu, Ruibao
    Li, Shijie
    Hou, Xunbo
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345